P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY

• A. F. Herrera,
• D. Lavie,
• N. A. Johnson,
• A. Avigdor,
• P. Borchmann,
• C. Andreadis,
• A. Bazargan,
• G. Gregory,
• C. Keane,
• T. Inna,
• V. Vucinic,
• P. L. Zinzani,
• H. Zhang,
• P. Pillai,
• P. Marinello,
• J. Timmerman

Affiliations

A. F. Herrera

1 City of Hope, Duarte, United States of America

D. Lavie

2 Hadassah Medical Center, Jerusalem, Israel

N. A. Johnson

3 Jewish General Hospital, Montreal, Canada

A. Avigdor

4 Sheba Medical Center, Ramat Gan, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

P. Borchmann

5 University Hospital of Cologne, Cologne, Germany

C. Andreadis

6 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America

A. Bazargan

7 University of Melbourne, Melbourne, and St Vincent’s Hospital, Fitzroy

G. Gregory

8 School of Clinical Sciences at Monash Health, Monash University, Melbourne

C. Keane

9 Princess Alexandra Hospital, Brisbane, Australia

T. Inna

10 Rambam Health Care Campus, Haifa, Israel

V. Vucinic

11 University of Leipzig Medical Center, Leipzig, Germany

P. L. Zinzani

12 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy

H. Zhang

13 Merck & Co., Inc., Kenilworth

P. Pillai

13 Merck & Co., Inc., Kenilworth

P. Marinello

13 Merck & Co., Inc., Kenilworth

J. Timmerman

14 UCLA Medical Center, Los Angeles, United States of America